TY - JOUR
T1 - Comparison of Three Survival Scores in a Series of Patients ≥80 Years of Age Irradiated for Bone Metastases
AU - Rades, Dirk
AU - Delikanli, Cansu
AU - Schild, Steven E.
AU - Kristiansen, Charlotte
AU - Tvilsted, Soren
AU - Janssen, Stefan
N1 - Publisher Copyright:
© 2023 International Institute of Anticancer Research. All rights reserved.
PY - 2023/2
Y1 - 2023/2
N2 - Background/Aim: Very elderly patients irradiated for bone metastases likely benefit from individualized treatments. A specific survival score was created for this group and compared to existing instruments. Patients and Methods: Ninety-six patients aged 80+ irradiated for bone metastases were retrospectively evaluated. Dose-fractionation regimen plus twelve characteristics were evaluated for survival. Results: In the Cox regression model, performance status and tumor type were significant and used for the score, which included three groups (5-7, 8-12, and 14 points) with 6-month survival rates of 15%, 52%, and 90%. Positive predictive values (PPVs) regarding death ≤6 months were 85% (new score), 100% (previous 65+ score), and 84% (previous score for any age). The new instrument and the 65+ score were also very accurate regarding survival. Since PPV regarding death was calculated from only four patients for the 65+ score, this PPV may be less conclusive than that for the new instrument. Conclusion: The new score appears useful for patients aged 80+ irradiated for bone metastases.
AB - Background/Aim: Very elderly patients irradiated for bone metastases likely benefit from individualized treatments. A specific survival score was created for this group and compared to existing instruments. Patients and Methods: Ninety-six patients aged 80+ irradiated for bone metastases were retrospectively evaluated. Dose-fractionation regimen plus twelve characteristics were evaluated for survival. Results: In the Cox regression model, performance status and tumor type were significant and used for the score, which included three groups (5-7, 8-12, and 14 points) with 6-month survival rates of 15%, 52%, and 90%. Positive predictive values (PPVs) regarding death ≤6 months were 85% (new score), 100% (previous 65+ score), and 84% (previous score for any age). The new instrument and the 65+ score were also very accurate regarding survival. Since PPV regarding death was calculated from only four patients for the 65+ score, this PPV may be less conclusive than that for the new instrument. Conclusion: The new score appears useful for patients aged 80+ irradiated for bone metastases.
UR - http://www.scopus.com/inward/record.url?scp=85146900322&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/4421925d-7a79-33f1-9aa8-5747bf997793/
U2 - 10.21873/anticanres.16221
DO - 10.21873/anticanres.16221
M3 - Journal articles
C2 - 36697108
AN - SCOPUS:85146900322
SN - 0250-7005
VL - 43
SP - 801
EP - 807
JO - Anticancer Research
JF - Anticancer Research
IS - 2
ER -